Physician profile
Stephen E Gunn
NPI 1073511572
$798.70
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $235 · 2023: $259 · 2024: $35.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $155.76 | 2022-2024 | |
| Atricure, INC. | $111.30 | 2022 | |
| Medtronic, INC. | $92.05 | 2023 | Avalus |
| E.R. Squibb & Sons, L.L.C. | $73.39 | 2021 | |
| Edwards Lifesciences Corporation | $67.80 | 2022-2023 | Inspiris Resilia Aortic Valve |
| Janssen Pharmaceuticals, INC | $62.21 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $47.88 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.41 | 2022-2023 | |
| Silk Road Medical, INC. | $28.56 | 2021 | |
| Amarin Pharma, INC. | $20.78 | 2021 | |
| Organogenesis INC. | $19.96 | 2023 | Puraply |
| Abbott Laboratories | $17.39 | 2024 | Xact |
| Astrazeneca Pharmaceuticals LP | $16.65 | 2021 | |
| Olympus America INC. | $16.32 | 2021 | |
| Depuy Synthes Sales INC. | $16.29 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $15.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Gunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.